Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Early treatment escalation to biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) following methotrexate (MTX) failure in new-onset rheumatoid arthritis (RA) does not ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

There is a bidirectional association between rheumatoid arthritis (RA ... muscle and bone diseases. Various treatments are available. Non-pharmacological treatment includes physical therapy ...

A recent study by Maheen Asif and team unveiled great outcome of abatacept in delaying the progression of rheumatoid ...

Chronic joint pain is a problem that affects millions of people worldwide. It can make everyday activities like walking, ...

Study to determine which treatments best for which inflammatory arthritis patients should result in patients being better ...

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.

Nurse-led care effectively reduces disease activity and improves self-efficacy in patients with rheumatoid arthritis, ...

ORYN-1001 is under clinical development by Oryn Therapeutics and currently in Phase I for Rheumatoid Arthritis.